conditionally replicative adenovirus 3/5-delta
Biologicalexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT01531244)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- conditionally replicative adenovirus 3/5-delta
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01531244 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | Washington University in St. Louis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1